Gain Therapeutics to Participate in Maxim Growth Summit
Gain Therapeutics, Inc. (Nasdaq: GANX), a cutting-edge biotechnology firm focused on developing innovative allosteric small molecule therapies, is excited to announce its participation in the upcoming Maxim Growth Summit. This notable event is set for October 22nd to 23rd in New York City.
Leadership Spotlight: Gene Mack
The President and CEO of Gain Therapeutics, Gene Mack, is scheduled to engage in a dynamic discussion during the summit. The panel titled "Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories" will delve into novel treatment approaches currently being explored for various neurodegenerative diseases.
Understanding the Maxim Growth Summit
The Maxim Growth Summit is more than just a conference; it gathers the brightest minds in various industries to share insights on trends and advancements. Attendees will have the chance to learn from leading figures, including keynote speakers like Larry Kudlow from Fox News and Christopher Ruddy, CEO of Newsmax Media.
Collaborative Discussions
The event is designed for networking and knowledge sharing. Roundtable discussions led by Maxim Research Analysts will provide a platform for CEOs from small and mid-cap companies, covering sectors ranging from biotechnology to artificial intelligence and beyond.
Gain Therapeutics: Innovating for a Better Future
Gain Therapeutics is on a mission to change the landscape of treatment through its promising lead drug candidate, GT-02287. This innovative therapy is currently undergoing evaluation in a Phase 1b clinical trial for Parkinson's disease and has potential applications for other serious conditions, including Gaucher’s disease and Alzheimer's disease. The company also holds multiple undisclosed preclinical assets targeting a variety of genetic and metabolic disorders.
Unique Approach to Drug Development
What sets Gain Therapeutics apart is its advanced Magellan™ platform. This unique approach enables the discovery of small molecule modulators that can finely tune protein function, paving the way for groundbreaking treatments for diseases that have long been deemed difficult to address.
Interested Investors and Media Engagement
Gain Therapeutics invites interested parties to reach out for further discussions about its vision and innovative approaches. For those wanting to connect with Gain management at the summit, contacting a Maxim sales representative would be the first step to scheduling a meeting.
Contacting Gain Therapeutics
For inquiries related to investor relations, you can reach Apaar Jammu, Manager of Investor Relations and Public Relations, at ajammu@gaintherapeutics.com. For media relations, Nic Johnson and Elio Ambrosio from Russo Partners LLC can be contacted at nic.johnson@russopartnersllc.com or elio.ambrosio@russopartnersllc.com.
Frequently Asked Questions
What is Gain Therapeutics' main focus at the summit?
Gain Therapeutics aims to share insights on their innovative therapies for neurodegenerative diseases.
Who is participating in the panel discussion?
Gene Mack, the President and CEO of Gain Therapeutics, will lead the discussion on challenging therapeutic categories.
What is the significance of the Maxim Growth Summit?
This summit gathers industry leaders to discuss advancements and trends across multiple sectors including biotechnology.
What is GT-02287?
GT-02287 is Gain Therapeutics' lead drug candidate aimed at treating Parkinson’s disease and other associated conditions.
How can investors connect with Gain Therapeutics?
Interested investors can reach out through Gain's investor relations manager, Apaar Jammu, via email for discussions.
